Context: Prediabetes is associated with subclinical cardiac changes associated with heart failure development. Objective: We investigated diastolic function and its association with markers of glycation and inflammation related to cardiovascular disease in patients with prediabetes. We focused on individuals with prediabetes identified only by glycated hemoglobin A1c [HbA1c< 5.7% to 6.4% and normal fasting glucose (NFG) and normal glucose tolerance (NGT) after an oral glucose tolerance test (OGTT)]. Design: Cross-sectional study. Setting: Departments of Clinical and Experimental Medicine and Cardiology, University of Catania, Catania, Italy. Main Outcome Measures: HbA1c< OGTT, Doppler echocardiography, soluble receptor for advanced glycation end products (sRAGEs), and endogenous secretory RAGE (esRAGE) were evaluated. Patients: We recruited 167 subjects with NFG/NGT who were stratified according to HbA1c level: controls (HbA1c<5.7%) and HbA1c prediabetes (HbA1c 5.7% to 6.4%). Results: Patients with HbA1c prediabetes (n = 106) showed a lower peak mitral inflow in early diastole (E wave) to late diastolic atrial filling velocity (A wave) ratio (E/A ratio) than controls (n = 61) (1.10 ± 0.24 vs 1.18 ± 0.23; P < 0.05). They showed a higher left atrium volume (LAV) (28.4 6 5 vs 22.1 6 3; P < 0.05) and sphericity index (SI) (0.6 ± 0.06 vs 0.5 ± 0.05; P < 0.05). After multiple regression analyses, HbA1c, sRAGE, and esRAGE were the major determinants of E/A ratio, LAV, and SI. Conclusions: Subjects with HbA1c prediabetes exhibited subclinical cardiac alterations associatedwith sRAGE, esRAGE, and HbA1c. These subjects would not have been classified as having prediabetes on the basisof fastingglycemiaorpost-OGTT values.

HbA1c identifies subjects with prediabetes and subclinical left ventricular diastolic dysfunction

Di Pino, Antonino;Urbano, Francesca;Scicali, Roberto;D'AGATE, VERONICA;Piro, Salvatore;Tamburino, Corrado;Purrello, Francesco;Rabuazzo, Agata Maria
2017-01-01

Abstract

Context: Prediabetes is associated with subclinical cardiac changes associated with heart failure development. Objective: We investigated diastolic function and its association with markers of glycation and inflammation related to cardiovascular disease in patients with prediabetes. We focused on individuals with prediabetes identified only by glycated hemoglobin A1c [HbA1c< 5.7% to 6.4% and normal fasting glucose (NFG) and normal glucose tolerance (NGT) after an oral glucose tolerance test (OGTT)]. Design: Cross-sectional study. Setting: Departments of Clinical and Experimental Medicine and Cardiology, University of Catania, Catania, Italy. Main Outcome Measures: HbA1c< OGTT, Doppler echocardiography, soluble receptor for advanced glycation end products (sRAGEs), and endogenous secretory RAGE (esRAGE) were evaluated. Patients: We recruited 167 subjects with NFG/NGT who were stratified according to HbA1c level: controls (HbA1c<5.7%) and HbA1c prediabetes (HbA1c 5.7% to 6.4%). Results: Patients with HbA1c prediabetes (n = 106) showed a lower peak mitral inflow in early diastole (E wave) to late diastolic atrial filling velocity (A wave) ratio (E/A ratio) than controls (n = 61) (1.10 ± 0.24 vs 1.18 ± 0.23; P < 0.05). They showed a higher left atrium volume (LAV) (28.4 6 5 vs 22.1 6 3; P < 0.05) and sphericity index (SI) (0.6 ± 0.06 vs 0.5 ± 0.05; P < 0.05). After multiple regression analyses, HbA1c, sRAGE, and esRAGE were the major determinants of E/A ratio, LAV, and SI. Conclusions: Subjects with HbA1c prediabetes exhibited subclinical cardiac alterations associatedwith sRAGE, esRAGE, and HbA1c. These subjects would not have been classified as having prediabetes on the basisof fastingglycemiaorpost-OGTT values.
2017
Adolescent; Adult; Aged; Asymptomatic Diseases; Blood Glucose; Cross-Sectional Studies; Diastole; Fasting; Female; Glucose Tolerance Test; Glycated Hemoglobin A; Humans; Male; Middle Aged; Prediabetic State; Ventricular Dysfunction, Left; Young Adult; Endocrinology, Diabetes and Metabolism; Biochemistry; Endocrinology; Clinical Biochemistry; Biochemistry (medical)
File in questo prodotto:
File Dimensione Formato  
HbA(1c).pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Dimensione 176.89 kB
Formato Adobe PDF
176.89 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11769/315824
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 40
  • ???jsp.display-item.citation.isi??? 39
social impact